EP3911415A4 - Dapson-formulierungen und verfahren zu deren verwendung - Google Patents

Dapson-formulierungen und verfahren zu deren verwendung Download PDF

Info

Publication number
EP3911415A4
EP3911415A4 EP21742678.2A EP21742678A EP3911415A4 EP 3911415 A4 EP3911415 A4 EP 3911415A4 EP 21742678 A EP21742678 A EP 21742678A EP 3911415 A4 EP3911415 A4 EP 3911415A4
Authority
EP
European Patent Office
Prior art keywords
methods
same
dapsone
formulations
dapsone formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21742678.2A
Other languages
English (en)
French (fr)
Other versions
EP3911415A1 (de
Inventor
Houfar SEKHAVAT
Satish Asotra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pulmonem Inc
Original Assignee
Pulmonem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmonem Inc filed Critical Pulmonem Inc
Publication of EP3911415A1 publication Critical patent/EP3911415A1/de
Publication of EP3911415A4 publication Critical patent/EP3911415A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21742678.2A 2020-03-30 2021-03-30 Dapson-formulierungen und verfahren zu deren verwendung Pending EP3911415A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063001972P 2020-03-30 2020-03-30
US202063029685P 2020-05-25 2020-05-25
CA3083002 2020-06-10
PCT/CA2021/050425 WO2021195765A1 (en) 2020-03-30 2021-03-30 Dapsone formulations and methods of using same

Publications (2)

Publication Number Publication Date
EP3911415A1 EP3911415A1 (de) 2021-11-24
EP3911415A4 true EP3911415A4 (de) 2022-10-12

Family

ID=77927001

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21742678.2A Pending EP3911415A4 (de) 2020-03-30 2021-03-30 Dapson-formulierungen und verfahren zu deren verwendung

Country Status (2)

Country Link
EP (1) EP3911415A4 (de)
WO (1) WO2021195765A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230144186A1 (en) * 2020-04-21 2023-05-11 The Trustees Of The University Of Pennsylvania Quinine and its use to generate innate immune response
US12029814B1 (en) * 2023-10-04 2024-07-09 Subhash Dhawan Formulation of ear drops and methods for delivery thereof for treating upper respiratory infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022039286A1 (en) * 2020-08-17 2022-02-24 Lee Jong Hoon 4,4'-diaminodiphenyl sulfone as an inflammasome competitor of oral vaccine or therapeutics for sars-cov-2 or covid-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
CA2573114C (en) 2004-07-07 2012-08-14 Lundbeck Pharmaceuticals Italy S.P.A. Process for synthesis of 4-4'-diamino-diphenyl-sulfone
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2016016321A1 (en) 2014-08-01 2016-02-04 Seegpharm Sa Process for the synthesis of dapsone and its intermediates
KR20200124185A (ko) * 2019-11-16 2020-11-02 이종훈 코비드-19 예방 구강 백신 및 치료용 의약품으로서 인플라마솜 경쟁자 뎁손

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022039286A1 (en) * 2020-08-17 2022-02-24 Lee Jong Hoon 4,4'-diaminodiphenyl sulfone as an inflammasome competitor of oral vaccine or therapeutics for sars-cov-2 or covid-19

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALI AHMED S ET AL: "Pharmacological basis for the potential role of Azithromycin and Doxycycline in management of COVID-19", ARABIAN JOURNAL OF CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 14, no. 3, 10 January 2021 (2021-01-10), XP086498546, ISSN: 1878-5352, [retrieved on 20210110], DOI: 10.1016/J.ARABJC.2020.102983 *
GONG JING ET AL: "Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia", MEDRXIV, 26 February 2020 (2020-02-26), XP055953075, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.02.25.20025643v1.full.pdf> [retrieved on 20220819], DOI: 10.1101/2020.02.25.20025643 *
KANOH SOICHIRO ET AL: "Dapsone inhibits IL-8 secretion from human bronchial epithelial cells stimulated with lipopolysaccharide and resolves airway inflammation in the ferret", CHESTUNITED STATES09 FEB 2018, ELSEVIER INC, UNITED STATES, vol. 140, no. 4, 30 September 2011 (2011-09-30), pages 980 - 990, XP009538298, ISSN: 1931-3543, [retrieved on 20151216], DOI: 10.1378/CHEST.10-2908 *
See also references of WO2021195765A1 *

Also Published As

Publication number Publication date
EP3911415A1 (de) 2021-11-24
WO2021195765A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
EP3997115A4 (de) Il-2-zusammensetzungen und verfahren zur verwendung davon
EP3976638A4 (de) Il-2-zusammensetzungen und verfahren zur verwendung davon
EP4103662A4 (de) Polierzusammensetzungen und verfahren zur verwendung davon
EP4065114A4 (de) Formulierungen von ionenkanalmodulatoren und verfahren zur herstellung und verwendung von ionenkanalmodulatoren
EP3911415A4 (de) Dapson-formulierungen und verfahren zu deren verwendung
EP4127088A4 (de) Polierzusammensetzungen und verfahren zur verwendung davon
EP4103663A4 (de) Polierzusammensetzungen und verfahren zur verwendung davon
EP4010024A4 (de) Orale formulierungen von cannabisextrakten und ihre herstellungsverfahren
EP4142740A4 (de) Zusammensetzungen und verfahren zur verwendung davon
EP4110066A4 (de) Formulierungen und deren verwendungen
EP4005561A4 (de) Nanomicellenherstellung von icaritin und verfahren zu ihrer herstellung und verwendung davon
EP4153067A4 (de) Hemibrücke und verfahren zu ihrer herstellung und verwendung
EP4175943A4 (de) Bifunktionelle verbindungen und verfahren zu ihrer verwendung
EP4139378A4 (de) Zusammensetzungen zur schnellen hydrophoben oberflächenmodifikation und verfahren zur verwendung davon
EP4081047A4 (de) Enzymzusammensetzungen und verfahren zu ihrer herstellung
EP3950961A4 (de) Anwendung von kdm5a-gen und atrx-gen
EP4047087A4 (de) Konstruktion von high-fidelity-crispr/ascpf1-mutanten und anwendung davon
EP4084802A4 (de) Zusammensetzungen von hydrogelen und verfahren zur verwendung davon
EP4135687A4 (de) Polycannabinoiden, verbindungen, zusammensetzungen und verfahren zur verwendung
EP4081233A4 (de) Zusammensetzung und verfahren zur herstellung
EP4034099A4 (de) Pimobendan-formulierung und verfahren zur verwendung davon
AU2020901533A0 (en) Formulations and methods of use
EP3946642A4 (de) Sonnenschutzmittel und verfahren zur verwendung davon
AU2020903103A0 (en) Cannabinoid Formulations and Methods of Use
EP4093278A4 (de) Ästhetikverbessernde formulierungen und verfahren dafür

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210728

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064250

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0031140000

Ipc: A61K0031160000

A4 Supplementary search report drawn up and despatched

Effective date: 20220909

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20220905BHEP

Ipc: A61K 31/7052 20060101ALI20220905BHEP

Ipc: A61K 31/65 20060101ALI20220905BHEP

Ipc: A61K 31/16 20060101AFI20220905BHEP

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240305